Hantavirus Infection Is Inhibited by Griffithsin in Cell Culture
Punya Shrivastava-Ranjan, Michael K Lo, Payel Chatterjee, Mike Flint, Stuart T Nichol, Joel M Montgomery, Barry R O'Keefe, Christina F Spiropoulou, Punya Shrivastava-Ranjan, Michael K Lo, Payel Chatterjee, Mike Flint, Stuart T Nichol, Joel M Montgomery, Barry R O'Keefe, Christina F Spiropoulou
Abstract
Andes virus (ANDV) and Sin Nombre virus (SNV), highly pathogenic hantaviruses, cause hantavirus pulmonary syndrome in the Americas. Currently no therapeutics are approved for use against these infections. Griffithsin (GRFT) is a high-mannose oligosaccharide-binding lectin currently being evaluated in phase I clinical trials as a topical microbicide for the prevention of human immunodeficiency virus (HIV-1) infection (ClinicalTrials.gov Identifiers: NCT04032717, NCT02875119) and has shown broad-spectrum in vivo activity against other viruses, including severe acute respiratory syndrome coronavirus, hepatitis C virus, Japanese encephalitis virus, and Nipah virus. In this study, we evaluated the in vitro antiviral activity of GRFT and its synthetic trimeric tandemer 3mGRFT against ANDV and SNV. Our results demonstrate that GRFT is a potent inhibitor of ANDV infection. GRFT inhibited entry of pseudo-particles typed with ANDV envelope glycoprotein into host cells, suggesting that it inhibits viral envelope protein function during entry. 3mGRFT is more potent than GRFT against ANDV and SNV infection. Our results warrant the testing of GRFT and 3mGRFT against ANDV infection in animal models.
Keywords: antiviral; griffithsin; haemorrhagic fever; hantaviridae; hantavirus.
Copyright © 2020 Shrivastava-Ranjan, Lo, Chatterjee, Flint, Nichol, Montgomery, O'Keefe and Spiropoulou.
Figures
References
- Alonso D. O., Perez-Sautu U., Bellomo C. M., Prieto K., Iglesias A., Coelho R., et al. . (2020). Person-to-person transmission of andes virus in hantavirus pulmonary syndrome, argentina, 2014. Emerg. Infect. Dis. 26, 756–759. 10.3201/eid2604.190799
- Bird B. H., Shrivastava-Ranjan P., Dodd K. A., Erickson B. R., Spiropoulou F. C. (2016). Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome. Antiviral Res. 132, 66–69. 10.1016/j.antiviral.2016.05.014
- Brocato R. L., Hooper W. J. (2019). Progress on the prevention and treatment of hantavirus disease. Viruses 11:610. 10.3390/v11070610
- Chapman L. E., Mertz G. J., Peters C. J., Jolson H. M., Khan A. S., Ksiazek T. G., et al. . (1999). Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin study group. Antivir. Ther. 4, 211–219
- Emau P., Tian B., O'Keefe B. R., Mori T., McMahon J. B., Palmer K. E., et al. . (2007). Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J. Med. Primatol. 36, 244–253. 10.1111/j.1600-0684.2007.00242.x
- Ethier M., Krokhin O., Ens W., Standing K. G., Wilkins J. A., Perreault H. (2005). Global and site-specific detection of human integrin alpha 5 beta 1 glycosylation using tandem mass spectrometry and the StrOligo algorithm. Rapid Commun. Mass Spectrom. 19, 721–727. 10.1002/rcm.1844
- Hepojoki J., Strandin T., Vaheri A., Lankinen H. (2010). Interactions and oligomerization of hantavirus glycoproteins. J. Virol. 84, 227–242. 10.1128/JVI.00481-09
- Hooper J. W., Larsen T., Custer D. M., Schmaljohn S. C. (2001). A lethal disease model for hantavirus pulmonary syndrome. Virology 289, 6–14. 10.1006/viro.2001.1133
- Huiskonen J. T., Hepojoki J., Laurinmaki P., Vaheri A., Lankinen H., Butcher S. J., et al. . (2010). Electron cryotomography of Tula hantavirus suggests a unique assembly paradigm for enveloped viruses. J. Virol. 84, 4889–4897. 10.1128/JVI.00057-10
- Ishag H. Z., Li C., Huang L., Sun M. X., Wang F., Ni B., et al. . (2013). Griffithsin inhibits Japanese encephalitis virus infection in vitro in vitro and in vivoin vivo. Arch. Virol. 158, 349–358. 10.1007/s00705-012-1489-2
- Ishag H. Z., Li C., Wang F., Mao X. (2016). Griffithsin binds to the glycosylated proteins (E and prM) of Japanese encephalitis virus and inhibit its infection. Virus Res. 215, 50–54. 10.1016/j.virusres.2016.01.016
- Jonsson C. B., Figueiredo L. T., Vapalahti O. (2010). A global perspective on hantavirus ecology, epidemiology, and disease. Clin. Microbiol. Rev. 23, 412–441. 10.1128/CMR.00062-09
- Jonsson C. B., Hooper J., Mertz G. (2008). Treatment of hantavirus pulmonary syndrome. Antiviral Res. 78, 162–169. 10.1016/j.antiviral.2007.10.012
- Lo M. K., Spengler J. R., Krumpe L. R. H., Welch S. R., Chattopadhyay A., Harmon J. R., et al. . (2020). Griffithsin inhibits nipah virus entry and fusion and can protect Syrian golden hamsters from lethal nipah virus challenge. J. Infect. Dis. 221 (Suppl. 4), S480–S492. 10.1093/infdis/jiz630
- Lusvarghi S., Bewley A. C. (2016). Griffithsin: an antiviral lectin with outstanding therapeutic potential. Viruses 8:296. 10.3390/v8100296
- Martinez V. P., Bellomo C., San Juan J., Pinna D., Forlenza R., Elder M., et al. . (2005). Person-to-person transmission of Andes virus. Emerg. Infect. Dis. 11, 1848–1853. 10.3201/eid1112.050501
- McNulty S., Flint M., Nichol S. T., Spiropoulou F. C. (2013). Host mTORC1 signaling regulates andes virus replication. J. Virol. 87, 912–922. 10.1128/JVI.02415-12
- Mertz G. J., Miedzinski L., Goade D., Pavia A. T., Hjelle B., Hansbarger C. O., et al. (2004). Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. 39, 1307–1313. 10.1086/425007
- Meuleman P., Albecka A., Belouzard S., Vercauteren K., Verhoye L., Wychowski C., et al. . (2011). Griffithsin has antiviral activity against hepatitis C virus. Antimicrob. Agents Chemother. 55, 5159–5167. 10.1128/AAC.00633-11
- Millet J. K., Seron K., Labitt R. N., Danneels A., Palmer K. E., Whittaker G. R., et al. . (2016). Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin. Antiviral Res. 133, 1–8. 10.1016/j.antiviral.2016.07.011
- Mittler E., Dieterle M. E., Kleinfelter L. M., Slough M. M., Chandran K., Jangra K. R. (2019). Hantavirus entry perspectives and recent advances. Adv. Virus Res. 104, 185–224. 10.1016/bs.aivir.2019.07.002
- Mohr E. L., McMullan L. K., Lo M. K., Spengler J. R., Bergeron E., Albarino C. G., et al. . (2013). Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses. Antiviral Res. 120, 40–47. 10.1016/j.antiviral.2015.05.003
- Moulaei T., Alexandre K. B., Shenoy S. R., Meyerson J. R., Krumpe L. R., Constantine B., et al. . (2015). Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus. Retrovirology 12:6. 10.1186/s12977-014-0127-3
- O'Keefe B. R., Giomarelli B., Barnard D. L., Shenoy S. R., Chan P. K., McMahon J. B., et al. . (2010). Broad-spectrum in vitro in vitro activity and in vivoin vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J. Virol. 84, 2511–2521. 10.1128/JVI.02322-09
- O'Keefe B. R., Vojdani F., Buffa V., Shattock R. J., Montefiori D. C., Bakke J., et al. . (2009). Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U.S.A. 106, 6099–6104. 10.1073/pnas.0901506106
- Safronetz D., Falzarano D., Scott D. P., Furuta Y., Feldmann H., Gowen B. B. (2013). Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob. Agents Chemother. 57, 4673–4680. 10.1128/AAC.00886-13
- Schmaljohn C., Hjelle B. (1997). Hantaviruses: a global disease problem. Emerg. Infect. Dis. 3, 95–104. 10.3201/eid0302.970202
- Shi X., McCaughey C., Elliott M. R. (2003). Genetic characterisation of a Hantavirus isolated from a laboratory-acquired infection. J. Med. Virol. 71, 105–109. 10.1002/jmv.10446
- Shrivastava-Ranjan P., Bergeron E., Chakrabarti A. K., Albarino C. G., Flint M., Nichol S. T., et al. . (2016). 25-Hydroxycholesterol inhibition of Lassa virus infection through aberrant GP1 glycosylation. mBio 7:e01808–16. 10.1128/mBio.01808-16
- Shrivastava-Ranjan P., Flint M., Bergeron E., McElroy A. K., Chatterjee P., Albarino C. G., et al. . (2018). Statins suppress Ebola virus infectivity by interfering with glycoprotein processing. mBio 9:e00660–18. 10.1128/mBio.00660-18
- Shrivastava-Ranjan P., Rollin P. E., Spiropoulou F. C. (2010). Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J. Virol. 84, 11227–11234. 10.1128/JVI.01405-10
- Warner B. M., Stein D. R., Jangra R. K., Slough M. M., Sroga P., Sloan A., et al. . (2019). Vesicular stomatitis virus-based vaccines provide cross-protection against andes and sin nombre viruses. Viruses 11:645. 10.3390/v11070645
- Zeitlin L., Pauly M., Whaley J. K. (2009). Second-generation HIV microbicides: continued development of griffithsin. Proc. Natl. Acad. Sci. U.S A. 106, 6029–6030. 10.1073/pnas.0902239106
Source: PubMed